@worldpdcongress.bsky.socialJoin Caroline M. Tanner at the next Research Spotlight for a look at #Parkinsons prevention and precision medicine.
📅 October 13, 2026 | 🕚 11 AM ET / 4 PM UK
Learn more & register: https://www.worldpdcoalition.org/WPCResearchSpotlight2026
@rpeptide.bsky.socialThe Alpha-Synuclein used in this study is available from rPeptide!
Our Synuclein product line includes native and mutant sequences, labeled options, fragments, and preformed fibrils to support a wide range of studies. 🔬
@rpeptide.bsky.socialCould naturally occurring antibodies hold the key to treating Parkinson's Disease?
Research shows autoantibodies targeting Alpha-Synuclein's NAC region can block toxic aggregation, studied using rPeptide's ASyn and defined fragments. 🧠
@worldpdcongress.bsky.social🔬 In case you missed it: “Translating Basic Science Into Therapies for PD” with D. James Surmeier, PhD. on the latest WPC Research Spotlight.
🎥 Watch now: https://youtu.be/cnr-nxeZZzY?si=VO9OwcnNH2Q59yFp
@worldpdcongress.bsky.social🧠🌎 Stay informed. Stay connected. Subscribe to the WPC Blog for the latest from WPC.
👉 Visit worldpdcongress.org/contact to subscribe.
#WPC #Parkinsons #ParkinsonsResearch #ParkinsonsCommunity #blog
@worldpdcongress.bsky.social🧠 What happens when patients and scientists come together? Read our latest WPC blog, with Esther Labib-Kiyarash.
Read here: https://www.worldpdcongress.org/home/2026/8/28/the-king-of-causality-vs-the-queen-of-microbiome